GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » 5-Year Yield-on-Cost %

Biomarin Pharmaceutical (WBO:BMRN) 5-Year Yield-on-Cost % : 0.00 (As of May. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical 5-Year Yield-on-Cost %?

Biomarin Pharmaceutical's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Biomarin Pharmaceutical's 5-Year Yield-on-Cost % or its related term are showing as below:



WBO:BMRN's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.85
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Biomarin Pharmaceutical's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Biomarin Pharmaceutical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's 5-Year Yield-on-Cost % falls into.



Biomarin Pharmaceutical 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Biomarin Pharmaceutical is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Biomarin Pharmaceutical  (WBO:BMRN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Biomarin Pharmaceutical 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (WBO:BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (WBO:BMRN) Headlines

From GuruFocus

BioMarin to Participate in Three Investor Conferences in March

By PRNewswire PRNewswire 03-02-2023

AMERIPRISE FINANCIAL INC Buys 4, Sells 1 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023